Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site

Nature

Volumn 528, Issue 7583, 2015, Pages 570-574

  Ulaganathan, Vijay K ^a   Sperl, Bianca ^a   Rapp, Ulf R ^b   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCINE; MESSENGER RNA; PROTEIN SH2; STAT3 PROTEIN; FGFR4 PROTEIN, HUMAN; PHOSPHOTYROSINE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

AMINO ACID; CANCER; CELLS AND CELL COMPONENTS; CYTOPLASM; GENE EXPRESSION; MEMBRANE; MUTATION; POLYMORPHISM; PROTEIN; RODENT;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST CANCER; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENDOPLASMIC RETICULUM; EXON; FARNESYLATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GERMLINE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INNER MEMBRANE; MOUSE; MYRISTYLATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BREAST TUMOR; CELL LINE; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; GENE TARGETING; GENETICS; LUNG TUMOR; MALE; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXONS; FEMALE; GENE KNOCK-IN TECHNIQUES; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PHOSPHOTYROSINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84951320585     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16449     Document Type: Article

References (20)

1. Morimoto, Y. et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98, 2245-2250 (2003).
2. Frullanti, E. et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur. J. Cancer Prevention 20, 340-347 (2011).
3. Heinzle, C. et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 72, 5767-5777 (2012).
4. Xu, W. et al. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Eur. J. Cancer 46, 3332-3338 (2010).
5. Xu, B. et al. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer 11, 84 (2011).
6. Streit, S., Mestel, D. S., Schmidt, M., Ullrich, A. & Berking, C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br. J. Cancer 94, 1879-1886 (2006).
7. Spinola, M. et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J. Clin. Oncol. 23, 7307-7311 (2005).
8. Falvella, F. S. et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int. J. Cancer 124, 2880-2885, (2009).
9. Streit, S. et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int. J. Cancer 111, 213-217 (2004).
10. Bange, J. et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 62, 840-847 (2002).
11. Abecasis, G. R. et al.; 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
12. Sharpe, H. J., Stevens, T. J. & Munro, S. A comprehensive comparison of transmembrane domains reveals organelle-specific properties. Cell 142, 158-169 (2010).
13. Buss, J. E., Der, C. J. & Solski, P. A. The six amino-terminal amino acids of p60src are sufficient to cause myristylation of p21v-ras. Mol. Cell. Biol. 8, 3960-3963 (1988).
14. Shao, H. et al. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J. Biol. Chem. 279, 18967-18973 (2004).
15. Cunningham, F. et al. Ensembl 2015. Nucleic Acids Res. 43, D662-D669 (2015).
16. Hancock, J. F., Cadwallader, K., Paterson, H. & Marshall, C. J. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 10, 4033-4039 (1991).
17. Rotin, D. et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J. 11, 559-567 (1992).
18. Sandgren, E. P., et al. Inhibition of mammary gland involution is associated with transforming growth factor α but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res. 55, 3915-3927 (1995).
19. Parker, R. A. & Bermann, N. G. Sample size: more than calculations. Am. Stat. 57, 166-170 (2003).
20. Vizcaíno, J. A., et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature Biotechnol. 32, 223-226 (2014).